Different Characteristics of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Seropositive Male Optic Neuritis in China

Table 3

Comparison of visual outcomes and clinical prognosis in male AQP4-ON and MOG-ON groups.

	AQP4-ON	MOG-ON	value
No. of patients	32	44
BCVA at nadir at first onset, eyes, n	38	57	0.915
≤0.1	31 (81.6)	46 (80.7)
0.1–0.5	6 (15.8)	8 (14.0)
≥0.5	1 (2.6)	3 (5.3)
BCVA recovery at first onset, eyes, n	38	57	<0.001
≤0.1	16 (42.1)	4 (7.0)
0.1–0.5	4 (10.5)	0 (0.0)
≥0.5	18 (47.4)	53 (93.0)
BCVA recovery at last follow-up, eyes, n	57	75	<0.001
≤0.1	32 (56.1)	8 (10.7)
0.1–0.5	5 (8.8)	3 (4.0)
≥0.5	20 (35.1)	64 (85.3)
LogMAR at nadir at first onset, mean ± SD	1.92 ± 0.98	1.70 ± 0.88	0.255
LogMAR recovery at first onset, mean ± SD	1.05 ± 1.14	0.19 ± 0.59	<0.001
LogMAR recovery at last follow-up, mean ± SD	1.24 ± 1.10	0.26 ± 0.62	<0.001
Follow-up, month, mean ± SD	40.72 ± 39.11	37.18 ± 38.93	0.697
Recurrent ON in follow-up, n (%)	26 (81.2)	27 (61.4)	0.062
Relapse after steroid reduction or cessation, n (%)	1 (3.8)	16 (59.3)	<0.001
Time of first to second attack (months)	19.35 ± 26.52	24.18 ± 36.93	0.593
Relapse times in follow-up, mean ± SD	1.78 ± 1.52	2.18 ± 3.12	0.462
ARR, mean ± SD	0.73 ± 0.82	0.68 ± 1.06	0.820
Conversion to NMO, n (%)	9 (28.1)	3 (6.8)	0.012

; ; ON, optic neuritis; BCVA, best-corrected visual acuity; ARR, annualised relapse rate; NMO, neuromyelitis optica; logMAR, logarithm of the minimum angle of resolution.